Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Resecting primary tumors fails to boost survival in metastatic CRC

Publish date:: January 28, 2020

Key clinical point: Resecting primary tumors that are not causing symptoms does not prolong survival of unresectable metastatic colorectal cancer.

Major finding: Median overall survival was 25.9 months with primary tumor resection followed by chemotherapy and 26.7 months with chemotherapy alone (hazard ratio for death, 1.10; P = .69).

Study details: A phase 3 randomized controlled trial among 160 patients with untreated stage IV colorectal cancer who had asymptomatic primaries and up to three sites of synchronous unresectable metastases (iPACS trial).

Disclosures: Dr. Kanemitsu disclosed that he receives honoraria from Chugai Pharma, Covidien, Ethicon, and Intuitive Surgical, and that he has a consulting or advisory role with Covidien. The study was funded by a Health and Labor Sciences Research Grant for Clinical Cancer Research. Dr. Booth disclosed that he has no conflicts of interest.

Citation:

Kanemitsu Y et al. 2020 GI Cancers Symposium. Abstract 7.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,